A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection.

Carmelo Scarpignato Colin W HowdenEckhard LeifkeDarcy J MulfordGezim LahuAxel FaciusRichard H Hunt

Published in: Alimentary pharmacology & therapeutics (2023)

Vonoprazan 20 mg once- and twice-daily dosing demonstrated high, dose-dependent, 24-hour intragastric acid control in this PK/PD model, supporting clinical efficacy data in patients with acid-related disorders.

Keyphrases

helicobacter pylori
helicobacter pylori infection
high dose
endoscopic submucosal dissection
low dose
electronic health record
physical activity
stem cell transplantation
big data
gastroesophageal reflux disease
machine learning
deep learning